Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014

Published: Apr-2014 | Format: PDF | Global Markets Direct | Number of pages: 113 | Code: MRS - 1002

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope


The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Post-Traumatic Stress Disorder (PTSD) Overview 9
Therapeutics Development 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 11
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 12
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 14
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 20
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 21
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 22
Nanotherapeutics, Inc. 22
Neurocrine Biosciences, Inc. 23
Addex Therapeutics 24
Neuralstem, Inc. 25
Catalyst Pharmaceutical Partners, Inc. 26
Humanetics Corporation 27
NeuroNascent, Inc. 28
Azevan Pharmaceuticals, Inc. 29
Omeros Corporation 30
Intra-Cellular Therapies, Inc. 31
Vanda Pharmaceuticals Inc. 32
Marinus Pharmaceuticals, Inc. 33
Otsuka Holdings Co., Ltd. 34
Tonix Pharmaceuticals Holding Corp. 35
Sage Therapeutics 36
Istituto Italiano di Tecnologia 37
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
brexpiprazole - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PRX-3140 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
verucerfont - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
atorvastatin calcium - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
aprepitant - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ganaxolone - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
iloperidone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
mifepristone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
oxytocin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
7-Keto - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SRX-251 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SRX-246 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ITI-007 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NNI-351 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
mGluR7-NAM Program For Central Nervous System Disorders - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NSI-189 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
cyclobenzaprine hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
S-107 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ZL-006 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ADX-71743 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Dihydroxyflavone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TLR-4 Antagonists for CNS Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Immune Therapy For PTSD and Depression - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Inhibit FAAH for CNS Disorders - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
vigabatrin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates 88
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 104
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 105
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 106
Featured News & Press Releases 106
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 106
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 106
Dec 27, 2012: Biotie Reports Top-line Data From Phase II Study With Nepicastat In Post-traumatic Stress Disorder 107
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 107
Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 108
Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 108
May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder 110
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 110
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 110
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 111

Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2014 10
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanotherapeutics, Inc., H1 2014 22
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H1 2014 23
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics, H1 2014 24
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H1 2014 25
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2014 26
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation., H1 2014 27
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H1 2014 28
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H1 2014 29
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H1 2014 30
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 31
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H1 2014 32
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H1 2014 33
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 34
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2014 35
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sage Therapeutics, H1 2014 36
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Istituto Italiano di Tecnologia, H1 2014 37
Assessment by Monotherapy Products, H1 2014 38
Number of Products by Stage and Target, H1 2014 41
Number of Products by Stage and Mechanism of Action, H1 2014 44
Number of Products by Stage and Route of Administration, H1 2014 46
Number of Products by Stage and Molecule Type, H1 2014 48
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H1 2014 88
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2014 104
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2014 105
List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2014 10
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 38
Number of Products by Top 10 Target, H1 2014 39
Number of Products by Stage and Top 10 Target, H1 2014 40
Number of Products by Top 10 Mechanism of Action, H1 2014 42
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 43
Number of Products by Top 10 Route of Administration, H1 2014 45
Number of Products by Stage and Top 10 Route of Administration, H1 2014 46
Number of Products by Top 10 Molecule Type, H1 2014 47
Number of Products by Stage and Top 10 Molecule Type, H1 2014 48

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing